JP2018534323A - 脂肪肝の予防または処置用医薬組成物 - Google Patents

脂肪肝の予防または処置用医薬組成物 Download PDF

Info

Publication number
JP2018534323A
JP2018534323A JP2018526123A JP2018526123A JP2018534323A JP 2018534323 A JP2018534323 A JP 2018534323A JP 2018526123 A JP2018526123 A JP 2018526123A JP 2018526123 A JP2018526123 A JP 2018526123A JP 2018534323 A JP2018534323 A JP 2018534323A
Authority
JP
Japan
Prior art keywords
liver
combination
mannitol
composition
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018526123A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018534323A5 (cg-RX-API-DMAC7.html
Inventor
幼圃 胡
幼圃 胡
欣恬 何
欣恬 何
永恩 呉
永恩 呉
熙卉 唐
熙卉 唐
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sinew Pharma Inc
Original Assignee
Sinew Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sinew Pharma Inc filed Critical Sinew Pharma Inc
Publication of JP2018534323A publication Critical patent/JP2018534323A/ja
Publication of JP2018534323A5 publication Critical patent/JP2018534323A5/ja
Priority to JP2021064174A priority Critical patent/JP2021105037A/ja
Priority to JP2023127107A priority patent/JP7690526B2/ja
Priority to JP2025089492A priority patent/JP2025124769A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23B—PRESERVATION OF FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES; CHEMICAL RIPENING OF FRUIT OR VEGETABLES
    • A23B2/00—Preservation of foods or foodstuffs, in general
    • A23B2/70—Preservation of foods or foodstuffs, in general by treatment with chemicals
    • A23B2/725—Preservation of foods or foodstuffs, in general by treatment with chemicals in the form of liquids or solids
    • A23B2/729—Organic compounds; Microorganisms; Enzymes
    • A23B2/733—Compounds of undetermined constitution obtained from animals or plants
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/75—Rutaceae (Rue family)
    • A61K36/752—Citrus, e.g. lime, orange or lemon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Nutrition Science (AREA)
  • Botany (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pain & Pain Management (AREA)
  • Medical Informatics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicinal Preparation (AREA)
JP2018526123A 2015-11-19 2016-03-31 脂肪肝の予防または処置用医薬組成物 Pending JP2018534323A (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2021064174A JP2021105037A (ja) 2015-11-19 2021-04-05 脂肪肝の予防または処置用医薬組成物
JP2023127107A JP7690526B2 (ja) 2015-11-19 2023-08-03 脂肪肝の予防または処置用医薬組成物
JP2025089492A JP2025124769A (ja) 2015-11-19 2025-05-29 脂肪肝の予防または処置用医薬組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562257697P 2015-11-19 2015-11-19
US62/257,697 2015-11-19
PCT/CN2016/078039 WO2017084234A1 (zh) 2015-11-19 2016-03-31 预防或治疗脂肪肝的药物组合物

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021064174A Division JP2021105037A (ja) 2015-11-19 2021-04-05 脂肪肝の予防または処置用医薬組成物

Publications (2)

Publication Number Publication Date
JP2018534323A true JP2018534323A (ja) 2018-11-22
JP2018534323A5 JP2018534323A5 (cg-RX-API-DMAC7.html) 2019-05-09

Family

ID=58718029

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2018526123A Pending JP2018534323A (ja) 2015-11-19 2016-03-31 脂肪肝の予防または処置用医薬組成物
JP2021064174A Pending JP2021105037A (ja) 2015-11-19 2021-04-05 脂肪肝の予防または処置用医薬組成物
JP2023127107A Active JP7690526B2 (ja) 2015-11-19 2023-08-03 脂肪肝の予防または処置用医薬組成物
JP2025089492A Pending JP2025124769A (ja) 2015-11-19 2025-05-29 脂肪肝の予防または処置用医薬組成物

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2021064174A Pending JP2021105037A (ja) 2015-11-19 2021-04-05 脂肪肝の予防または処置用医薬組成物
JP2023127107A Active JP7690526B2 (ja) 2015-11-19 2023-08-03 脂肪肝の予防または処置用医薬組成物
JP2025089492A Pending JP2025124769A (ja) 2015-11-19 2025-05-29 脂肪肝の予防または処置用医薬組成物

Country Status (7)

Country Link
US (1) US10925854B2 (cg-RX-API-DMAC7.html)
EP (1) EP3391881A4 (cg-RX-API-DMAC7.html)
JP (4) JP2018534323A (cg-RX-API-DMAC7.html)
CN (2) CN107613968A (cg-RX-API-DMAC7.html)
HK (1) HK1244213A1 (cg-RX-API-DMAC7.html)
TW (1) TWI711464B (cg-RX-API-DMAC7.html)
WO (1) WO2017084234A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024525957A (ja) * 2021-08-20 2024-07-12 中国農業科学院鄭州果樹研究所 ヘスペレチン含有組成物およびその血糖降下における相乗的応用

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201890810A1 (ru) * 2015-09-24 2018-11-30 Синью Фарма Инк. Соединения, эффективные для лечения гепатотоксичности и стеатоза печени, и их применение
CN110151787A (zh) * 2018-02-12 2019-08-23 玛旺干细胞医学生物科技股份有限公司 护肝组合物及其用途
TWI691719B (zh) * 2018-10-19 2020-04-21 香港商阿瓦隆 海帕波有限公司 半乳糖快速定量檢測系統及其應用
EP3991728A4 (en) * 2019-06-25 2023-08-09 National Hospital Organization HEPATIC FIBROSIS INHIBITING AGENT AND BROWN FAT CELL ACTIVATING AGENT WITH TAXIFOLINE
CN112471376A (zh) * 2020-11-02 2021-03-12 辽宁康汇医学临床研究有限公司 一种防治酒精性脂肪肝的固体饮料及其制备方法
CN117205159A (zh) * 2023-09-04 2023-12-12 中国医学科学院药用植物研究所 一种自纳米组合物及制备方法与应用
CN119184297A (zh) * 2024-09-18 2024-12-27 中国农业大学 葛根素及其衍生物调控des1改善肝脏脂质堆积及其应用

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999053914A1 (en) * 1998-04-16 1999-10-28 Ajinomoto Co., Inc. Remedies for primary biliary cirrhosis
JP2004083468A (ja) * 2002-08-26 2004-03-18 Aotsubu:Kk アブラナ科植物の抽出物とその用途
WO2006135084A1 (ja) * 2005-06-14 2006-12-21 Kurume University 脂肪性肝炎または脂肪肝の予防または治療薬
JP2007182405A (ja) * 2006-01-10 2007-07-19 Univ Kurume 脂肪性肝疾患の改善治療薬
WO2009028457A1 (ja) * 2007-08-29 2009-03-05 Shinshu University 非アルコール性脂肪肝炎治療薬
JP2012520866A (ja) * 2009-03-17 2012-09-10 アプタリス・ファーマ・カナダ・インコーポレイテッド 高用量のウルソデオキシコール酸で非アルコール性脂肪性肝炎を治療する方法
US20140038921A1 (en) * 2011-04-20 2014-02-06 National Defense Education And Research Foundation New low side effect pharmaceutical composition containing antituberculosis drugs
WO2014158242A1 (en) * 2013-03-13 2014-10-02 Golden Biotechnology Corporation Method for the treatment of fatty liver disease
WO2015070396A1 (zh) * 2013-11-13 2015-05-21 财团法人国防教育研究基金会 无肝副作用的对乙酰胺基酚新复方组合

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4388328A (en) * 1981-10-15 1983-06-14 Warner-Lambert Company Sorbitol containing mixture encapsulated flavor
US5080910A (en) * 1990-05-15 1992-01-14 Werner-Lambert Company Stabilized chlorodeoxysugar sweetening agents in powder form and methods for preparing same
US5804165A (en) * 1996-07-24 1998-09-08 Arnold; Michael J. Antiplaque oral composition
JP4824886B2 (ja) * 2001-09-11 2011-11-30 長岡香料株式会社 フルクトース吸収阻害剤、組成物、および食品
DE602004015966D1 (de) * 2003-04-03 2008-10-02 Hayashibara Biochem Lab Lipidregulierendes mittel und dessen verwendung
CN101683411B (zh) * 2008-09-24 2012-09-19 汪鋆植 海棠提取物在制备保肝药物或保健食品中的用途
CN101744865B (zh) * 2008-12-18 2012-07-25 山东福田药业有限公司 一种木糖醇护肝片的制备方法
TR200904862A1 (tr) * 2009-05-29 2010-12-21 Sanovel İlaç San. Ve Ti̇c. A.Ş. Sukraloz formülasyonu ve üretim prosesi
CN101933900A (zh) * 2009-07-02 2011-01-05 天津瑞普生物技术股份有限公司 一种用于防治禽类肝病的复方制剂及其制备方法
JP2011231078A (ja) * 2010-04-30 2011-11-17 Nagaoka Koryo Kk 非アルコール性脂肪性肝疾患の予防および／または治療に有効な経口摂取用組成物
AR083417A1 (es) 2010-10-14 2013-02-21 Novartis Ag Composiciones farmaceuticas que contienen un dgat1 inhibidor
CN102908596B (zh) * 2011-08-05 2014-09-03 成都永康制药有限公司 一种治疗脂肪肝的中药组合物
BR102012033020A2 (pt) * 2011-12-22 2015-10-20 Int Flavors & Fragrances Inc composições para aumento da sensação de frescor
US10441560B2 (en) * 2013-03-15 2019-10-15 Mochida Pharmaceutical Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
MX2015014956A (es) * 2013-04-29 2016-08-08 Chigurupati Tech Private Ltd Toxicidad reducida en bebidas alcoholicas.
CN103432528A (zh) * 2013-08-23 2013-12-11 冯庄明 一种治疗非酒精性脂肪肝的中药制剂
EA201890810A1 (ru) * 2015-09-24 2018-11-30 Синью Фарма Инк. Соединения, эффективные для лечения гепатотоксичности и стеатоза печени, и их применение

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999053914A1 (en) * 1998-04-16 1999-10-28 Ajinomoto Co., Inc. Remedies for primary biliary cirrhosis
JP2004083468A (ja) * 2002-08-26 2004-03-18 Aotsubu:Kk アブラナ科植物の抽出物とその用途
WO2006135084A1 (ja) * 2005-06-14 2006-12-21 Kurume University 脂肪性肝炎または脂肪肝の予防または治療薬
JP2007182405A (ja) * 2006-01-10 2007-07-19 Univ Kurume 脂肪性肝疾患の改善治療薬
WO2009028457A1 (ja) * 2007-08-29 2009-03-05 Shinshu University 非アルコール性脂肪肝炎治療薬
JP2012520866A (ja) * 2009-03-17 2012-09-10 アプタリス・ファーマ・カナダ・インコーポレイテッド 高用量のウルソデオキシコール酸で非アルコール性脂肪性肝炎を治療する方法
US20140038921A1 (en) * 2011-04-20 2014-02-06 National Defense Education And Research Foundation New low side effect pharmaceutical composition containing antituberculosis drugs
WO2014158242A1 (en) * 2013-03-13 2014-10-02 Golden Biotechnology Corporation Method for the treatment of fatty liver disease
WO2015070396A1 (zh) * 2013-11-13 2015-05-21 财团法人国防教育研究基金会 无肝副作用的对乙酰胺基酚新复方组合

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DIABETES, vol. 64, JPN6020004962, May 2015 (2015-05-01), pages 1658 - 1669, ISSN: 0004210027 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024525957A (ja) * 2021-08-20 2024-07-12 中国農業科学院鄭州果樹研究所 ヘスペレチン含有組成物およびその血糖降下における相乗的応用
JP7588274B2 (ja) 2021-08-20 2024-11-21 中国農業科学院鄭州果樹研究所 ヘスペレチン含有組成物およびその血糖降下における相乗的応用

Also Published As

Publication number Publication date
CN107613968A (zh) 2018-01-19
HK1244213A1 (zh) 2018-08-03
EP3391881A1 (en) 2018-10-24
TWI711464B (zh) 2020-12-01
US10925854B2 (en) 2021-02-23
CN116440143A (zh) 2023-07-18
JP2023145714A (ja) 2023-10-11
TW201718015A (zh) 2017-06-01
JP2025124769A (ja) 2025-08-26
EP3391881A4 (en) 2020-03-11
US20180117003A1 (en) 2018-05-03
JP7690526B2 (ja) 2025-06-10
JP2021105037A (ja) 2021-07-26
WO2017084234A1 (zh) 2017-05-26

Similar Documents

Publication Publication Date Title
JP7690526B2 (ja) 脂肪肝の予防または処置用医薬組成物
Liang et al. Mulberry leaves extract ameliorates alcohol-induced liver damages through reduction of acetaldehyde toxicity and inhibition of apoptosis caused by oxidative stress signals
Yang et al. Apigenin prevents metabolic syndrome in high-fructose diet-fed mice by Keap1-Nrf2 pathway
Harrison et al. Advances in the understanding and treatment of nonalcoholic fatty liver disease
Li et al. Fenretinide attenuates lipopolysaccharide (LPS)-induced blood-brain barrier (BBB) and depressive-like behavior in mice by targeting Nrf-2 signaling
Cintra et al. Interleukin-10 is a protective factor against diet-induced insulin resistance in liver
Yuan et al. Protective effect of resveratrol on kidney in rats with diabetic nephropathy and its effect on endoplasmic reticulum stress.
Wei et al. Di-(2-ethylhexyl) phthalate increases plasma glucose and induces lipid metabolic disorders via FoxO1 in adult mice
Niwa et al. Ipomoea batatas and Agarics blazei ameliorate diabetic disorders with therapeutic antioxidant potential in streptozotocin-induced diabetic rats
Song et al. A polysaccharide from Alhagi honey protects the intestinal barrier and regulates the Nrf2/HO-1-TLR4/MAPK signaling pathway to treat alcoholic liver disease in mice
Chen et al. Tetramethylpyrazine reduces inflammation in the livers of mice fed a high fat diet
Kang et al. Opuntia ficus-indica seed attenuates hepatic steatosis and promotes M2 macrophage polarization in high-fat diet–fed mice
Tian et al. Selegiline ameliorated dyslipidemia and hepatic steatosis in high-fat diet mice
Sun et al. Baicalin and N-acetylcysteine regulate choline metabolism via TFAM to attenuate cadmium-induced liver fibrosis
Minxuan et al. Fisetin attenuates high fat diet-triggered hepatic lipid accumulation: A mechanism involving liver inflammation overload associated TACE/TNF-α pathway
Mohamed et al. Fenofibrate A peroxisome proliferator activated receptor-α agonist treatment ameliorates Concanavalin A-induced hepatitis in rats
Ding et al. Lipid modulatory activities of Cichorium glandulosum Boiss et Huet are mediated by multiple components within hepatocytes
Du et al. Effects of Rhizoma Alismatis extract on biochemical indices and adipose gene expression in oleic acid-induced hepatocyte injury in Jian carp (Cyprinus carpio var. Jian)
Zhang et al. Tangduqing granules attenuate insulin resistance and abnormal lipid metabolism through the coordinated regulation of PPARγ and DGAT2 in type 2 diabetic rats
Zhao et al. Vitamin K2 protects mice against non-alcoholic fatty liver disease induced by high-fat diet
JP5799082B2 (ja) 眞黄精又は黄精抽出物の新規な用途
Shan et al. Caffeine in hepatocellular carcinoma: Cellular assays, animal experiments, and epidemiological investigation
Sun et al. Gastroprotective effect of fucoidan from Sargassum siliquastrum against ethanol-induced gastric mucosal injury
TWI634886B (zh) Compound composition for liver-free side effects with reduced liver fat for treating symptoms of non-alcoholic fatty liver disease (NAFLD)
Zwolak et al. Hyperreactivity of blood leukocytes in patients with NAFLD to ex vivo lipopolysaccharide treatment is modulated by metformin and phosphatidylcholine but not by alpha ketoglutarate

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190320

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190320

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20200131

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200212

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200508

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200710

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200812

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20201208